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I want to begin by discussing Henny Penny.
1 To the best of my knowledge, 
she has not been patented nor is she a registered trademark, but as is ap-
propriate for my presentation, she is eminently in the public domain. This 
story may be one of the first encounters most of us have had with the values 
relevant to risk assessment and since most public presentations about risk 
are in the form of stories, albeit television or newspaper, it may help to re-
mind ourselves how well this childhood pastoral legacy fits present day cir-
cumstances.
You know the story. Henny Penny is in the barnyard when suddenly she 
is hit on the head by an acorn. She immediately assumes the sky is falling 
and that she must hurry to tell those in authority. She recruits a number of 
her companions to join in the mission. On the way she and her friends are 
seduced by a wily fox to take a short cut from which she and her friends are 
never heard from again.
It presents a role model which derides conclusions based upon a foolish 
reaction to Nature because this response leads to even greater disaster. Na-
ture is very regular; she does not play tricks such as sending the sky to fall 
like rain and we can depend on that when we try to figure out what is going
1 Presently there are 10 listings for this story in Canada and 8 in the United States 
in current Books in Print.
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on around us. True natural events which can be very destructive are not 
ruled out, but we can deal with these precisely because they are a part of 
common sense understanding of what the world is about. We must respect 
and can trust nature in its untampered state.
The presence of technology has altered this picture. Based on science, it 
tries to harness nature’s regularity and tame her power to produce predict-
able outcomes upon which a host of human ac-
tivities can be formed. On this view, animal 
domestication maybe one of the earliest ex-
amples of a technological change being im-
posed upon the natural world. Bronowsky 
(1973) has argued that the discovery of a culti- 
vatable form of wheat is one of the primal dis-
coveries of civilization. But there is a slight ca-
veat to which I would like to call your attention. 
Most people do not view the domestication of 
animals or the discovery of wheat as technology. 
They see it as an example of human ability to ex-
ploit natural abundance, fundamental to the 
Story of Creation which gives biblical authoriza-
tion to pastoral goodness. A contemporary example of how pervasive this at-
titude is, is found in Michael Fox’s introduction to his book, Superpigs and 
Wondercorn: The Brave New World of Biotechnology...and Where It All May 
Lead (1992). In it he describes the need to repair “this dispoiled planet” and 
the need to “dress and keep” the Garden of Eden.
The views just presented are not easily reconcilable. They offer conflict-
ing approaches to the course of human life. Most Americans know little of 
the history of science and technology. What for the average North American 
resident symbolizes the state of contemporary agriculture as well as what to 
expect from biotechnology consists of a brew of naivete and skepticism— 
Arcadia or the Monster. It is not hard to find vestiges of this style of moral 
understanding in current conflicts over the licensing of agricultural products 
having biotechnological modifications.
Here are three illustrations which I believe represent current versions of 
this state of Americana: First, there is the belief that if you grow something, it 
represents contact with a reality absolutely fundamental for human exist-
ence. Apartment dwellers with their three tomato plants 30 stories above the 
street can really get into this business of growing things. (Of course, it may 
also be a last desperate attempt to find a replacement for the wooden toma-
toes which adorn the average salad.) At this level, these plants can signify a 
desire to maintain one of the last vestiges of the pastoral dream from which 
most of life has been wrenched—roots, if you will.
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Second, there is the paradox inherent in the abundance which North 
American agriculture exemplifies. On the one hand, the industry remains 
one of the major unsolvable problems for modern governments, far outstrip-
ping the complications currently posed by the challenge to transform our de-
fense industry. On the other hand, this politicalization of agriculture has 
succeeded in disillusioning the very people who wallow in its largess. The 
difference in the effectiveness of the pork barrel in determining agricultural 
policy, while at the same time the failure of legislators to protect the consum-
ing public from the risks inherent in the raising and preparation of food for 
consumption, has not gone unnoticed, viz federal inspection of the meat 
packing industry.
Third, the effects of biotechnology as it applies to agriculture are a source 
of concern both rational and irrational. There is a real ignorance of science 
and how it works especially as related to probabil-
ity. There is a belief that the effects of biotechno-
logical manipulation pose a risk for a possible but 
unknown catastrophe. To the extent that the changes 
biotechnology proposes initiate an element of risk 
to those who use its products, they demand a form 
of control unknown to the simple morality of a pas-
toral ideal in conflict with an apocalyptic vision of 
a mechanical universe which would destroy the Gar-
den. To the extent that the present effectiveness of
the protective role of government has a high failure rate with no attribu-
tion of responsibility, there is real fear as to what Food and Drug Adminis-
tration (FDA) approval means in terms of protecting the consumer. This view 
of the failure to protect from risk can be dismissed as the continual failure 
of moral politics to understand and regulate the new face of agriculture. Finally, 
the extent to which contemporary patterns of food distribution make it diffi-
cult for the average person to chopse on the basis of accurate information— 
increases the paranoia of a public ignorant of science and fuels the notion that 
current regulatory procedures controlling agricultural biotechnology are 
untrustworthy.
That Americans were far from being prepared for a change of moral cli-
mate was suggested in 1964 by Leo Marx in his monograph, The Machine in 
the Garden. His review of American literature from the colonial period to the 
present day suggests that we are stunned by the magnitude of the protean con-
flict figured by the machine’s increasing domination of the visible world.
This recurring metaphor of contradiction makes vivid, as no other figure 
does, the bearing of public events upon private lives. It discloses that our in-
herited symbols of order and beauty have been divested of meaning. It com-
pels us to recognize that the aspirations once represented by the symbol of an
...the effects of 
biotechnology as it 
applies to agricul-
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ideal landscape have not, and probably cannot be, embodied in our traditional 
institutions. It means that an inspiriting vision of a humane community has 
been reduced to a token of individual survival. To change the situation we re-
quire new symbols of possibility, and although the creation of these symbols is 
in some measure the responsibility of artists, it is in greater measure the re-
sponsibility of society. The machine’s sudden entrance into the garden pre-
sents a problem that ultimately belongs not to art, but to politics (Marx, 1964).
...the challenge presented 
by the new age is to 
transform our simplistic 
view of moral conflict 
with a nuanced theory of 
ethical accounting.
CLUES FROM BIOETHICS: INFORMED CONSENT
As I see it, the challenge presented by the new age is to transform our simplis-
tic view of moral conflict with a nuanced theory of ethical accounting. It re-
quires vocabulary which reflects awareness of 
the content of the public values just presented 
and a theoretical structure that incorporates the 
reason of science into our political reality. The 
paradigmatic instance of this change is played 
out in the history of bioethics over the last quar-
ter century. Now a mature enterprise, lessons 
from what has happened in medicine may pro-
vide some clues as to how traditional moral re-
sponses to biotechnology might be recast in a mold which will resolve current 
social deadlock.
The history of bioethics has been covered elsewhere (Clouser, 1970). For 
our purposes, I would emphasize its source in the awareness that individuals 
have the right to be protected from exploitation by those who are offering them 
medical care and treatment. Over the years, a series of cases have helped delin-
eate the circumstances under which this protection should apply (NIH, 1980). 
The result has been the creation of a working system whereby technology is 
supported at the same time protecting those who would be its beneficiaries or 
its victims (e.g., Halushka vs. University of Saskatchewan, 1965). In the center 
of this system has been FDA. There are three tiers to this system which are 
indispensable to its functionality: Tier One—the establishment of ethical prin-
ciples which must be realized in action; Tier Two—the demand that all activity 
must be backed by data which has been subject to the statistical demands de-
manded by contemporary science; and Tier Three—the development of a pro-
cess whereby the first two criteria may be acted upon. In addition, and indis-
pensable to the working of the system, is a definition of roles which separate 
the function of regulatory as opposed to developmental responsibilities. Let 
me describe in more detail the constituents of this practice:
Tier One
The establishment of ethical principles which provide a moral arena for action 
Here the dominant normative force has been autonomy. Functionally, this 
has led to the enshrinement of informed consent as its most important ex-
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pression. Subject to a caveat covering emergency treatment for children and 
the mentally incompetent, every act with its costs and benefits must first be 
understood before being accepted by an individual patient. The extension 
of risk to patients other than mentally competent adults is severely restricted 
to those interventions for which the benefit is clearly demonstrable. As it has 
developed, the practice of principled action has been most completely ex-
plored as it applies to individuals. Principles governing society, such as jus-
tice and fairness, have only recently been the subject of more sophisticated 
attention, particularly as it applies to the availability of health care. Here it is 
obvious that notions such as that of “the common good” are highly contro-
versial and the sharing of both costs and benefits has proved highly difficult 
to implement in a socially acceptable manner.
Tier Two
The requirement that all projected actions must be the subject of investigations 
which produce data conforming to current scientific practice as regards statisti-
cal probability is essential to developing a meaningful cost/benefit analysis. Of 
more than a little interest to those concerned about the effects of biotechnol-
ogy are the practices which cover the development and use of new drugs. The 
three-phase trial system which moves from animals to human subjects is used 
to determine general parameters of risk and efficacy (NIH, 1977). Only after 
passing all three phases can a drug be licensed for the task for which it was 
tested. This system is not perfect, but its shortcomings have not prevented it 
from working. Of some concern is the practice of using only adult males in 
the Phase 3 trials, the final step before licensing. The failure to include chil-
dren, women and the elderly in these protocols has led many to question the 
conclusions, particularly about dosage and side effects which are included in 
the approval documentation. The practice of asking physicians to report ad-
verse effects as they occur in the “field” has only been partially successful in 
developing a more complete dossier about each drug.
Tier Three
The development of a process through which principles may be combined with 
data to produce a distribution system which is safe within defined limits accept-
able to the consuming public is the final component in the practice Institu-
tional Review Boards (IRBs) must review all trials using human subjects for 
both scientific merit and ethical responsibility (Levine, 1961). The record 
has been neither incident nor scandal free.2 There was the famous thalido-
mide affair and perhaps more to our concern, the cancer risks to the daugh-
ters of mothers who had been prescribed diethylstilbestrol (DES) during
2 The most outspoken of recent critics has probably been Ivan Illich. c.f. Limits to Medi-
cine: Medical Nemesis: The Expropriation of Health. McClelland and Stewart, 
Toronto, Ont. 1976.
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pregnancy as an attempt to avoid early miscarriages (Potter, 1991). There 
have been detractors who insist that the present system is far too conserva-
tive in a time of crisis such as that produced by AIDS. Nonetheless, it is criti-
cal not to lose sight of the core process. It is the principle of informed con-
sent. This has allowed for the implementation of such widely differing prac-
tices as giving bioengineered growth hormone to children, gene therapy for 
cancer, and xenografts from hogs with transgenically altered immune sys-
tems. Each individual can in theory and in practice, supported by social con-
sensus, assume risk because each is free to choose whether or not to receive 
defined benefits. Consent is also understood as a process with several grada-
tions—with increased risk in relation to benefit requiring more awareness of 
what is being accepted.
The additional element in the practice just described is what, I believe, ac-
counts for its level of public acceptance. This is the attempt to separate regu-
latory responsibilities from developmental functions—the role of govern-
ment as distinct from that of industry. Jane Jacobs in her recent book, Sys-
tems of Survival-a Dialogue on the Moral Foundations of Commerce and Poli-
tics (1992), argues that these groups represent two distinct modes or syn-
dromes, the Guardian and the Commercial, which are essential to the func-
tioning of human society. The first, guardianship, arises from the behavior 
which we share with animals—foraging for food and protecting our territo-
ries. Guardians work in the armed forces and police, government ministries
and their bureaucracies, legislatures, courts 
and organized religions. The second, Com-
mercial, arises from trade and production of 
goods and is an endeavor unique to human 
beings. These two modes of survival have 
produced two discrete and contradictory 
ethical systems and are the source of conflict 
when the precepts appropriate to the guard-
ian system are imposed on the commercial 
and vice versa. In its everyday functionality, 
this means that drug companies are free to 
be as inventive as possible—expressed as profitability—so long as they oper-
ate within the structures and regulations designed to protect society. But, 
and this is a major qualifier, the individual (a patient in this case) is still free 
to determine whether he or she accepts the risks and benefits made available 
by this symbiotic structure. In the case of health care, the point where this 
assumption of risk and benefits occurs is not in terms of a market relation-
ship, but as informed consent. As we turn to the matter of agricultural bio-
technology, we encounter a significant difference in the risk/benefit struc-
There is great difficulty in 
exercising informed 
consent [in agricultural 
biotechnology] 
because...the monolithic 
distribution system tends 
to restrict action to all or 
nothing.
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ture. There is great difficulty in exercising informed consent because, as we 
have previously noted, the monolithic distribution system tends to restrict 
action to all or nothing. You either buy the product available or you do with-
out it. In practical terms, consumers are left with what appears to be an irra-
tional response—massive group threats of boycott—to what is more reason-
ably viewed as a need for rational discussion and understanding.3
CURRENT CONTROVERSIES: AN ETHICAL ANALYSIS 
In this final section I would like to review a number of current controversies 
involving bioengineered agricultural applications, subjecting them to the 
three-tiered structure I have proposed and which has been developed in the 
course of bioethics as well as the survival ethics proposed by Jane Jacobs (1992).
I will begin with the Tier Two of the structure. This is the requirement 
that all projected actions must be the subject of scientific investigation.
I think that what is most upsetting to the scientific community is the fact that 
on this criteria, agricultural biotechnology has performed quite well. Let me 
begin by comparing the cases of bovine and porcine somatatropin. The evi-
dence would suggest that, from the point of animal welfare, bST is accept-
able—the review of testing seeming to indicate that there is no increased risk 
of mastitis in animals given the hormone, as well as attesting that there is no 
contamination of the milk by bST. The effect upon hogs by bST has not been 
so benign and until the adverse effects on the animals can be controlled, on 
the basis of animal welfare alone, scientific evidence would tend to support 
withholding acceptance of this method of enhancing lean qualities of pork.
In both of these examples, there does not appear to be serious objection to in 
vivo investigations. When it comes to Bf-toxin in food crops to control in-
sects, the issue is more complex. Recent field tests of corn involving trans-
genic manipulation of an insecticidal protein derived from Bacillus thurin- 
giensis (Bt) has proved it to be highly resistant to heavy field infestation of the 
European corn borer (Koziel et al., 1993). Here, I believe, our experience 
from medical history may be helpful in delineating the issues. Are the long-
term effects of Bt-toxin similar to what has happened to the effectiveness of 
our recent treatments for tuberculosis or to the eradication of small pox?
Or to put the problem in another way, what is the evidence that the long-
term effects of Bf-toxin on pest control will be more successful than produced 
by the heavy use of insecticides? Then, there is the controversy of the Flavr 
Savr™ tomato. The likelihood that its use of the kanamycin-resistance gene
3 Compare the campaign waged by Jeremy Rifkin against the Flavr Savr™ tomato 
which involved threated boycott of McDonald’s and Campbell’s products as well 
as the enlistment of prominent chefs to refuse their use.
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as a marker in the reverse-RNA antisense process will produce human side 
effects by hooking up with the wrong bacteria during the digestive process is 
highly remote (Hoyle, 1992). The evidence appears to be at a level of cer-
tainty which would be perfectly acceptable had this 
been a drug being considered for licensing. It is not an 
overstatement to suggest that the level of scientific re-
search and testing involved in biotechnology is at least 
as good as that available in the health care field. If we 
want to understand what may be the problem, we must 
turn to the other tiers which round out the consumer 
protection package available to the user of health care.
This brings us to another look at Tier One—the 
establishment and implementation of ethical principles 
to provide a normative element that protects the user/ 
consumer from exploitation. I do not believe that different principles apply 
here from those which are used in our evaluation of health care. But our pre-
vious examination does suggest that informed consent by the individual to 
the risk/benefit involved in food product use has a more complex ethical ap-
plication. 4 Furthermore, the nature of risk is such that the specific instance 
in which it will appear cannot be determined, so that concepts of common 
good may unwittingly but unfairly single out victims. Theoretically it could 
be possible to establish a compensation system to help ease the morbidity/ 
mortality of victims, but the multisource of present risk for disease such 
as cancer would make the application of this worthy idea almost impos-
sible. So, I believe the resolution of our ethical case must take into ac-
count the general insistence of the American consumer that the decision to 
assume risk must be an individual one, even if there are notable instances 
when the actual rational weighing of outcome is honored more in the breach 
as, for example, in deciding to get a driver’s license.
Can the process powers of Tier Three produce a distribution system 
which is safe and accountable by reworking the ways in which we apply our 
ethical principles? We may get a better sense of what this orientation is up 
against by asking some leading questions. Is McDonald’s likely to give cus-
tomers a choice of Flavr Savr™ tomatoes or regular ones? What about 
Campbell’s? Labeling is one possible response, but it is ethically acceptable 
as reflecting the existence of choice only if alternatives are readily available. 
Merely spelling out contents is not enough because what is of paramount im-
How can govern-
ment regulate 
with one hand 
when its other 
hand is in the 
business of 
agriculture?
4 For a different approach see: MacLean, D. “Social Values and the Distribution of 
Risk.” In Values at Risk. D. MacLean, ed. Rowman & Allanheld, Totawa, NJ. 1986. 
p 75-93.
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portance is some indication of risk. Is there the equivalent available to us of 
a Phase 3 drug trial which could produce acceptable accounting of risk? (It would 
of course add considerably to the cost of food in the short run.) Who could run 
a large trial of 10,000 to 20,000 randomized participants? For what period 
of time? Most carcinogens are notoriously slow in producing symptoms of dis-
ease so we would probably have to accept animal evi-
dence here. Possibly a consensus conference, something 
like the Presidential Commission on Bioethics (1980) 
that produced the original ethical guidelines for health 
care could, in addition to offering insight as to the rela-
tionship of autonomy to common good, clarify the roles 
of government and industry. For example, only govern-
ment in the exercise of its guardianship role could ex-
tend the common good to include the ecosystem and 
produce the regulations to which development must con-
form. Certainly we need less of the kind of argument presented by Michael W. 
Fox (as cited by Johnson, 1993) that implies that eliminating profit motives is 
in the public interest, because it confuses even further the difference between 
protection and innovation, both of which are vital to our future welfare. This 
discussion has also shown that the social interaction we have called “process” 
is all too often subsumed under the term politics. Nowhere is this more true 
than in that paradoxical enterprise of our society called agriculture.
Jane Jacobs (1992) offers the vision that the human past and future is 
tied in quite absolute ways to the proper use of both guardian and commer-
cial enterprise. The application of biotechnology to agriculture seems des-
tined for more of the same unproductive confusion and mistrust by our citi-
zenry unless we can sort out the current confusion as to which is responsible 
for what. How can government regulate with one hand when its other hand 
is in the business of agriculture? Since the time frame of all living creatures 
is from the human perspective, is it nonetheless a fitting human response to 
expect that profitability take a somewhat longer perspective than the next two 
to five years? I would offer, as one possibility, that the combination of values 
which currently drives American skepticism about the future promised by 
biotechnology is demanding a standard of accounting closer to a view of time 
expressed by the evolution of natural life than the short term perspective that 
plagues both government and industry. Sub specie aeternitatis indeed!
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